United States - English - NLM (National Library of Medicine)

handyman stuff, llc - menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - for the temporary relief of minor aches and pains of the muscles and joints associated with arthritis, simple backache, sprains, bruises and strains.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - dental - densah® burs are indicated for use to prepare osteotomies for dental implant placement in the mandible or maxilla. the parallel pin is for use as a paralleling guide with the densah® burs.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - dental - densah® tapered pilot drill is used to create the initial hole in bone to prepare an osteotomy for dental implant placement and monitor the drilling depth.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - orthopaedics - healavis 1.0% is indicated for the treatment of pain in osteoarthritis (oa) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g.,acetaminophen(paracetamol)).

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - orthopaedics - synolis v-a products are indicated to reduce pain and improve mobility due to degenerative changes in the knee joint linked to osteoarthritis.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - gastroenterology & urology - the compat ella enteral feeding pump is intended to be used for the delivery of enteral tube feed and hydration at controlled rates to the gastrointestinal system. it is intended for use with adult and paediatric patients requiring enteral feeding and hydration in hospital, nursing home and home care environments.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - pathology - the idylla™ braf mutation test, performed on the biocartis idylla™ system, is an in vitro diagnostic test for the qualitative detection of v600e/e2/d and v600k/r/m mutations in codon 600 of the braf gene. the idylla™ braf mutation test uses dna liberated from formalin-fixed paraffin-embedded (ffpe) tissue sections from human melanoma tumor cells. the test is a sample-to-result real-time pcr. the results of the idylla™ braf mutation test may be useful for the physician to aid in identifying metastatic melanoma patients who may benefit from braf targeted therapy. the idylla™ braf mutation test is not intended to diagnose metastatic melanoma. the physician shall take other disease factors into account, other than the patient’s mutation status, to make a therapy decision.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - pathology - the biocartis idylla™ egfr mutation test performed on the biocartis idylla™ system, is an in vitro diagnostic test intended for the qualitative detection of exon 18 (g719a/s/c), exon 21 (l858r, l861q), exon 20 (t790m, s768i) mutations, exon 19 deletions and exon 20 insertions in the egfr oncogene. the idylla™ egfr mutation test uses formalin-fixed, paraffin-embedded (ffpe) tissue sections from human non-small cell lung cancer (nsclc) tissue. the idylla™ egfr mutation test covers the entire process from ffpe sample to result, including fully integrated sample preparation, liberation of nucleic acids, real-time pcr amplification and detection, and data analysis.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - pathology - the idylla™ kras mutation test, performed on the biocartis idylla™ system, is an in vitro diagnostic test for the qualitative detection of mutations in codons 12, 13, 59, 61, 117 or 146 of the kras oncogene. the idylla™ kras mutation test, from sample to result, starts with formalin-fixed, paraffin-embedded (ffpe) human colorectal cancer (crc) tissue to liberate dna for subsequent real-time pcr amplification and detection. the idylla™ kras mutation test is intended to determine the tumor kras mutation status of patients with metastatic colorectal cancer at diagnosis and to facilitate treatment decisions within a multidisciplinary team. the idylla™ kras mutation test is not intended to diagnose colorectal cancer.

Singapore - English - HSA (Health Sciences Authority)

andaman medical pte. ltd. - pathology - the idylla™ nras mutation test, performed on the biocartis idylla™ system, is an in vitro diagnostic test for the qualitative detection of mutations in codons 12, 13, 59, 61, 117, 146 of the nras gene. the idylla™ nras mutation test, from sample to result, starts with the liberation of dna from formalin-fixed, paraffin-embedded (ffpe) human colorectal cancer tissue, followed by real-time pcr amplification and detection.